Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Oncolys BioPharma continues sharp rise as MHLW panel approves full authorization for oncolytic virus Telomelysin injection
Oncolys BioPharma Inc. <4588> extended sharp gains. Before the market open, the company announced that a Ministry of Health, Labour and Welfare subcommittee on May 21 approved the regulatory authorization of its oncolytic virus Telomelysin injection, lifting the shares. The drug is indicated for esophageal cancer patients ineligible for curative resection or chemoradiotherapy. Following official approval and the drug price listing process, the product is slated for launch during the current fiscal year as planned.
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
OSAKA GAS falls for third straight day despite share cancellation announcement
South Korean KOSPI opens at 7,873.12 on the 22nd, up 57.53 points
Hulic falls sharply on concerns over short-term supply-demand deterioration from overseas share offering
MEDIA LINKS surges on IWAN-based media transmission connection test
KPP GROUP hits new year-to-date high on Murakami fund stake
Geniee falls on unauthorized access to GENIEE MA tool
JAPAN CASH MACHINE rises on dividend increase
A&D HOLON Holdings continues to rise on stock purchases by Strategic Capital
Kioxia remains resilient with market cap in 30 trillion yen range, funds continue to support memory-related stocks
Tokyo stocks open higher, buoyed by Dow's record high